We report a patient with acute promyelocytic leukaemia (APL) who received two doses of gemtuzumab ozogamicin for advanced disease. Previous treatments included front-line all-trans retinoic acid and anthracyclines, polychemotherapy consolidation, salvage chemotherapy for the first relapse followed by autologous stem cell transplantation (ASCT), arsenic trioxide for the second relapse followed by a second ASCT and then high-dose methotrexate for more advanced systemic disease with central nervous system involvement. The patient achieved prolonged haematological and molecular remission after monotherapy with gemtuzumab ozogamicin given at the time of the third relapse.
Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gentuzumab ozogamicin (MylotargTM CMA-676) / Petti, Mc; Pinazzi, Mb; Diverio, D; Romano, A; Petrucci, Mt; DE SANTIS, S; Meloni, Giovanna; Tafuri, Agostino; Mandelli, Franco. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 0007-1048. - 115:1(2001), pp. 63-65. [10.1046/j.1365-2141.2001.03091.x]
Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gentuzumab ozogamicin (MylotargTM CMA-676).
MELONI, Giovanna;TAFURI, Agostino;MANDELLI, Franco
2001
Abstract
We report a patient with acute promyelocytic leukaemia (APL) who received two doses of gemtuzumab ozogamicin for advanced disease. Previous treatments included front-line all-trans retinoic acid and anthracyclines, polychemotherapy consolidation, salvage chemotherapy for the first relapse followed by autologous stem cell transplantation (ASCT), arsenic trioxide for the second relapse followed by a second ASCT and then high-dose methotrexate for more advanced systemic disease with central nervous system involvement. The patient achieved prolonged haematological and molecular remission after monotherapy with gemtuzumab ozogamicin given at the time of the third relapse.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
